SELF-EMULSIFYING FENOFIBRATE FORMULATIONS
BACKGROUND AND SUMMARY OF THE INVENTION
The present invention relates to a pharmaceutical dosage form of fenofibrate with a potential for enhanced bioavailability.
The term "composition" as used herein shall mean any composition containing a therapeutic agent along with inactive ingredients that are themselves pharmaceutically acceptable in the quantities administered.
The term "carrier medium" as used herein is to be understood as defining the material in which the drug (i.e. fenofibrate) is dissolved. The carrier medium may be a single or a combination or mixture of ingredients included as solvents, surfactants, diluents or for other purposes.
Fenofibrate or 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-propanoic acid 1-methylethyl ester is a potent lipid modulator agent; it offers unique and significant clinical advantages over existing products in the fibrates class of drugs. Fenofibrate produces substantial reductions in plasma triglyceride levels in hypertriglyceridemic patients and in plasma cholesterol and LDL-cholesterol in hyperhyperchoiesterolemic and mixed dyslipidemic patients.
Fenofibrate is a prodrug which immediately after absorption is hydrolyzed by tissue and plasma esterases to its active major metabolite, fenofibric acid. Fenofibric acid is responsible for the pharmacological activity and its plasma half-life is about 20 hours. Fenofibrate is practically
insoluble in water, it is poorly and variably absorbed and has to be taken with food.
Fenofibrate was first available in a pharmaceutical dosage form (Lipanthyl® also marketed under the trademarks Lipidil® and Lipantil®) consisting of a hard gelatin capsule containing fenofibrate, lactose, pregelatinized starch and magnesium stearate. After oral administration, during a meal, about 60% of the dose of this conventional form is effectively absorbed and found in the blood as fenofibric acid (Weil et al., The metabolism and disposition of 14C-fenofιbrate in human volunteers, Drug. Metabol. Dispos. Biol. Fate. Chem., 18 (1990) 115-120).
Historically, in order to improve the intestinal absorption, another pharmaceutical dosage form was introduced (Lipidil Micro®, also marketed under the trademarks Lipanthyl® and Tricos®). European Patent Application 330,532 and U.S. patent 4,895,726 disclose a fenofibrate composition in which the fenofibrate powder is co-micronized with a solid wetting agent. Sodium lauryl sulfate is described as the wetting agent of choice. The co-micronized powder so obtained is mixed with capsule filling excipients such as lactose, starch, cross-linked polyvinyl pyrrolidone and magnesium stearate. A study comparing this formulation (Lipidil Micro®) to the conventional form (Lipidil®) had showed statistically significant increase in bioavailability with the former.
However, co-micronization of the active drug fenofibrate with the wetting agent sodium lauryl sulfate, although necessary, has several drawbacks such as irritation of mucosal membranes of the gastrointestinal
tract. In addition, micronization is a time consuming and costly operation and the filling of hard gelatin capsules with a micronized powder is a difficult operation when taking into account weight variation homogeneity.
European Patent Application 724,877 describes fenofibrate powder co-micronized with a wetting agent in association with a vitamin E component (tocopherol and/or its organic acid ester) for treating or preventing disorders associated with lipoprotein oxidation.
U.S. patent 4,800,079 relates to a medicinal composition in the form of granules with controlled release of fenofibrate. Each granule includes an inert core, a layer based on fenofibrate and a protective layer. Fenofibrate is present in the form of crystalline microparticles of dimensions not greater than 30 μm.
U.S. patent 4,961,890 relates to a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles (< 30 μm in diameter) within a multilayer layer inert matrix.
U.S. patent 5,545,628 relates to a pharmaceutical composition for treating hyperlipidemia or hypercholesterolemia or both in a mammal, by providing an effective amount of each of fenofibrate and an excipient including one or more polyglycolyzed glycerides (generally mixtures of known monoesters, diesters and triesters of glycerols and known monoesters and diesters if polyethylene glycols). The polyglycolyzed glycerides may be obtained by partial transesterification of tri glycerides
with polyethylene glycol or by esterification of glycerol and polyethylene glycol with fatty acids.
European Patent Application 757,911 relates to a fenofibrate pharmaceutical dosage form in which fenofibrate is in solution in diethylene glycol monoethyl ether (EMDG) which is a non ionic surfactant.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is a graph showing the data obtained in Example 12, and Figure 2 is a graph showing the results obtained in Example 13.
SUMMARY OF THE INVENTION
In accordance with the present invention it has now surprisingly been found that particularly stable fenofibrate formulations that self emulsify in aqueous medium giving an average particle size in a range of about 10 nm to about 10 microns and that have improved bioavailability characteristics, are obtainable. Also described are self-emulsifying preconcentrates that disperse, without the input of high energy (i.e., other than mixing energy to cause dispersion), to form droplets of average size of up to about 10 microns.
Accordingly, this invention provides a pharmaceutical composition in the form of a self-emulsifying preconcentrate comprising fenofibrate as the active ingredient solubilized in a carrier medium comprising at least one hydrophobic component, at least one hydrophilic component and at least one surfactant.
The self-emulsifying systems and their corresponding preconcentrates described in this invention consist of a hydrophobic component, an ingredient selected from triglycerides, diglycerides, monoglycerides, free fatty acids, and fatty acid esters (such as fatty acid esters of hydroxyalkanes or of dihydroxyalkanes) and derivatives thereof, individually or in combination. Preferably the surfactant is a non-ionic surfactant or a mixture of non-ionic surfactants. The invention is also characterized as optionally including a hydrophilic component, for instance a hydroxyalkane such as ethanol and/or a dihydroxyalkane such as 1,2- propylene glycol and/or a polyethylene glycol having an average molecular weight of less than or equal to 1000.
DETAILED DESCRIPTION OF THE INVENTION
A self-emulsifying preconcentrate comprising fenofibrate of the present invention must contain a hydrophobic component, a surfactant and optionally a hydrophilic component.
The surfactant and hydrophilic component are needed for the composition to form in aqueous medium a self-emulsifying system having an average particle size of between about 10 nm and about 10 microns, and preferably at most 5 microns. They may also help enhance the solubility and stability of fenofibrate in the formulation.
The hydrophobic component is needed because if it is not incorporated in appropriate amounts in the formulation, precipitation of
fenofibrate will be observed upon mixing of the composition with an aqueous medium and/or on storage. Similar observations may be made for the hydrophilic and surfactant components.
Based on the above, appropriate combinations or mixtures of a hydrophobic component, a surfactant and a hydrophilic component (when used) with fenofibrate are necessary to obtain a stable microemulsion preconcentrate that would yield upon mixing with an aqueous medium a stable dispersion with an average particle size of between about 10 nm and about 10 microns.
Preferred as hydrophobic components are triglycerides, diglycerides, monoglycerides, free fatty acids, and fatty acid esters and derivatives thereof, individually or in combination. Examples of hydrophobic components include but are not limited to propylene glycol dicaprylate/caprate, caprilic/capric triglyceride, caprylic/capric/linoleic triglyceride, e.g., synthetic medium chain triglycerides having C _i2 fatty acid chains or other derivatized (synthetic) triglycerides of the type known and commercially available under Miglyol 810, 812, 818, 829 and 840, linoleic acid, linoleic acid ethyl ester, fish oils as free fatty acids, their esterification and their transesterification products, e.g., of the type known and commercially available under EPAX 6000 FA, EPAX 4510 TG, individually or in combination. Additional examples include vegetable oils and Ci 2-18 fatty acid mono-, di- and triglycerides prepared by individual admixing or as transesterification products of vegetable oils (such as soybean oil, almond oil, sunflower oil, olive oil or corn oil) with glycerol.
Preferred as hydrophilic components are 1,2-propylene glycol, ethanol and polyethylene glycol having an average molecular weight of less than or equal to 1000, individually or in combination.
More preferred as hydrophilic components are 1 ,2-propy lene glycol and ethanol, individually or in combination.
Especially preferred as hydrophilic components is a combination or mixture of 1,2-propylene glycol and ethanol.
Compositions of the current invention will include, in addition to fenofibrate, the hydrophobic components and the optional hydrophilic components, and at least one surfactant. Examples of suitable surfactants are:
1. Polyoxyethylene-sorbitan-fatty acid esters; e.g., mono- and tri-lauryl, palmityl, stearyl and oleyl esters; e.g., products of the type known as polysorbates and commercially available under the trade name "Tween".
2. Polyoxyethylene fatty acid esters, e.g., polyoxyethylene stearic acid esters of the type known and commercially available under the trade name Myrj.
3. Polyoxyethylene castor oil derivatives, e.g., products of the type known and commercially available as Cremophors. Particularly suitable are polyoxyl 35 castor oil (Cremophor EL) and polyoxyl 40 hydrogenated castor oil (Cremophor RH40).
4. alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS).
5. PEG glyceryl fatty acid esters such as PEG-8 glyceryl caprylate/caprate (commercially known as Labrasol), PEG-4 glyceryl caprylate/caprate (Labrafac Hydro WL 1219), PEG-32 glyceryl laurate (Gelucire 44/14), ), PEG-6 glyceryl mono oleate (Labrafil M 1944 CS), PEG-6 glyceryl linoleate (Labrafil M 2125 CS).
6. Propylene glycol mono- and di-fatty acid esters, such as propylene glycol laurate, propylene glycol caprylate/caprate; also diethylene glycol monoethyl ether, commercially known as transcutol.
7. Sorbitan fatty acid esters, such as the type known and commercially available under the trade name Span (e.g., Span 20).
8. Polyoxyethylene-polyoxypropylene co-polymers, e.g., products of the type known and commercially available as Pluronic or Poloxamer.
9. Glycerol triacetate.
10. Monoglycerides and acetylated monoglycerides, e.g., glycerol monooleate, glycerol monostearate and mono-and di- acetylated monoglycerides.
Suitable surfactants are not limited to those mentioned above, but may include any compound that would enhance the galenic properties of the preconcentrate.
Compositions in accordance with the present invention may include other ingredients in addition to the drug, one or more hydrophobic components, one or more hydrophilic components and one or more surfactants. For example, the composition may include, in addition to the forgoing, one or more ingredients, additives or diluents such as
pharmaceutically acceptable polymeric or inorganic materials, anti- oxidants, preserving agents, flavoring or sweetening agents and so forth.
Compositions in accordance with the present invention may be liquid or solid at ambient temperature. They may be filled in soft or hard gelatin capsules in the form of liquid composition, molten composition, or granules or powder (if composition is solid at ambient temperature and was cooled and processed before filling). Coating may be also applied to capsules or tablets. The preconcentrate may be also diluted with water to obtain stable emulsion that may be employed as drinking formulations, for example.
The relative proportion of fenofibrate and the other ingredients in the composition of the current invention, will vary depending whether it is delivered as a self-emulsifying preconcentrate or after dilution with water, depending on the particular ingredients and the desired physical properties of the formulation. Especially desired concentration limits in the self- emulsifying preconcentrate:
1. Oil phase: from 10 to 85% w/w of the preconcentrate. The oil phase may consist of triglycerides, diglycerides, monoglycerides, free fatty acids, propylene glycol mono or diesters and free fatty acids, esters and derivatives thereof, individually or in combination.
2. Cumulative amounts of surfactants: from 10 to 80% w/w of the preconcentrate.
3. Cumulative amounts of hydrophilic components, such as 1,2- propylene glycol and/or ethanol and/or a polyethylene glycol having an average molecular weight of less than or equal to 1000 : from 0%
to 40%) w/w of the preconcentrate. The total of all ingredients will be 100%.
The oral dosage range for a typical preconcentrate according to the invention per 100 mg fenofibrate is estimated to vary between 700-3000 mg. For lower amounts of drug, the total quantity of ingredients may be proportionally reduced.
The following are illustrative but non limiting examples of compositions in accordance with the present invention.
Examples
In the following examples, the ingredients were weighed out into appropriate containers in the amounts described below. In all examples described below, a clear liquid was obtained upon appropriate mixing and heating.
The formulations represented in the following examples were prepared by mixing the oil components with the drug powder followed by the addition of surfactants and cosurfactants as indicated. The composition may be prepared at room temperature or heated to 40-50°C to accelerate the solubilization process. Several mixing techniques can be used ranging from mechanical stirring and agitation to sonication.
All compositions shown below give liquid or semi-solid preconcentrates at room temperature.
In vitro testing of the preconcentrates was carried out by diluting the preconcentrate in 50-100 fold water or simulated gastric fluid with gentle mixing or shaking. The aqueous medium temperature varied between 20 and 37°C. Particle size analysis was then carried out using a Nicomp 370. Data reported in the following examples correspond to volume weighted distributions.
Example 1: Composition comprising 100 mg fenofibrate
Mean particle size : 50 nm
Excipients Quantity (mg)
Miglyol 810 250
Linoleic acid 130
Tween 80 200
Myrj 52 170
VitE-TPGS 108
Ethanol 126
1,2-propylene 124 glycol
Example 2: Composition comprising 100 mg fenofibrate Mean particle size : 20 nm
Excipients Quantity (mg)
Miglyol 810 250
Linoleic acid 130
Tween 80 375
VitE-TPGS 76
Ethanol 126
1,2-propylene 125 glycol
Example 3: Composition comprising 100 mg fenofibrate
Mean particle size : 30 nm
Excipients Quantity (mg)
Linoleic acid ethyl 350 ester
Tween 80 350
VitE-TPGS 90
Span 20 100
Ethanol 150
1,2-propylene glycol 75
Example 4: Composition comprising 100 mg fenofibrate
Mean particle size : 30 nm
Excipients Quantity (mg)
Miglyol 840 360
Tween 40 235
Tween 80 235
VitE-TPGS 75
Span 20 150
Ethanol 150
1,2-propylene glycol 75
Example 5: Composition comprising 100 mg fenofibrate Mean particle size : 90 nm
Excipients Quantity (mg)
Miglyol 840 360
Tween 40 270
Tween 80 114
VitE-TPGS 75
Cremophor EL 160
Ethanol 140
1,2-propylene 75 glycol
Example 6: Composition comprising 100 mg fenofibrate Mean particle size: 10 nm
Excipients Quantity (mg)
Miglyol 810 280
Linoleic acid 130
Tween 80 520
Ethanol 120
Labrasol 20
Example 7: Composition comprising 100 mg fenofibrate Mean particle size: 25 nm
Excipients Quantity (mg)
Miglyol 810 280
Linoleic acid 130
Tween 80 484
Ethanol 40
Labrasol 54
1,2-propylene 20 glycol
Example 8: Composition comprising 100 mg fenofibrate Mean particle size: 40 nm
Excipients Quantity (mg)
Miglyol 840 435
Tween 80 473
Ethanol 100
Span 80 127
Example 9: Composition comprising 100 mg fenofibrate Mean particle size: 45 nm
Excipients Quantity (mg)
Miglyol 840 360
Linoleic acid 75
Tween 80 464
Ethanol 120
Example 10: Composition comprising 100 mg fenofibrate Mean particle size 40 nm
Excipients Quantity (mg)
Miglyol 840 435
Span 20 135
Tween 80 470
Ethanol 100
Example 11: Composition comprising 100 mg fenofibrate Mean particle size 40 nm
Excipients Quantity (mg)
Miglyol 840 429
Inwitor 742 233
Cremophor EL 291
Example 12: Effect of Dilution on Particle Size of Self-Emusifying (SE-) Fenofibrate Formulation
The fenofibrate preconcentrate prepared in Example 11 was diluted in various ratios either with deionized water (DW) or with simulated gastric fluid (SGF) with gentle mixing at 35-37°C. Volume weighted particle size analysis of the diluted emulsion was then performed using Nicomp 370 particle size analyzer. As can be seen from the data presented in the following table, the formation of microemulsion is independent of the dilution factor.
Example 13: Increase in Oral Bioavailability of SE-Fenofibrate in Beagle Dogs
Oral administration of the SE-fenofibrate of Example 10 was compared with the commercially available Lipanthyl® 67M formulation in two male and two female beagle dogs per group. Each group was administered either the commercial formulation or SE-fenofibrate of Example 10 each containing 67 mg of the drug per dose. Blood samples after each administration were collected at 0.5, 1, 2, 3, 4, 6, 24, and 48 hours. Fenofibrate concentration of each blood plasma sample was determined by high pressure liquid chromatography by monitoring for the level of the metabolite, finofibric acid. The data are presented in the attached graph, Figure 1, in which solid squares represent the self- emulsifying fenofibrate preconcentrate of the present invention and the solid triangles represent the commercial product. At equivalent dose, the bioavailability of the drug was about 30% higher in case of the SE- fenofibrate of Example 10 than the commercial formulation. In a similar study in human subjects (n=8 per group), the bioavailability of SE- fenofibrate of Example 11 was about 57% higher than that of the
commercial formulation.
Example 14: Effect of Food on Oral Bioavailability of SE-Fenofibrate in
Human Subjects
The SE-fenofibrate composition used in Example 11 was tested in human volunteers. The study consisted of oral administration of the fenofibrate formulation to eight human volunteers per group in a cross-over design in fed or fasted state. Each group was administered fenofibrate containing 67 mg of the drug. Blood samples were taken before and after each administration at various time points over 120 hours. Drug concentration in blood samples was determined by high pressure liquid chromatography by monitoring for the level of the metabolite, fenofibric acid. The data are presented in Fig. 2. At equivalent dose, the ratio of bioavailability in fasted and fed state was 0.99 (90%) confidence interval: 0.91-1.06) indicating that the bioavailability of SE-fenofibrate formulation is independent of food intake.